SEC Form 4 · accession 0001814238-26-000013
Royalty Pharma plc · RPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Hite
Officer — EVP & Chairman, Partnering
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 5:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001802768
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary SharesF1 | Aug 5, 2026 | A | 11,002 | $0.00 | A | 470,401 | I | By SCH Investment Partners LLC |
| Class A Ordinary Shares | holding | — | — | — | 40,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
Remarks
In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.